That's why they removed the implementation chart from the quarterly reporting over a year ago treating share holders with contempt. They seem unable to implement more than 3500 a quarter. It's not a bottleneck it's a glass ceiling. 60,000 implemented so far and 200,000 needed for break even for global ops. Do the maths and that's into the 2030s. I've submitted the question about implementation limitations at the last 4 webinars and my question hasn't been aired. I assume PD gets to see the questions beforehand and agrees with NWR what questions are to be asked.
Also no response from my emails, although I'm sure I was blacklisted 2 years ago.
Some on the forums said it was to do with the lag in signing up to rolling out and you would see it later in the year. Well we've had 2 years of it now and no difference. So that argument no longer holds any water. FDA approval does not equal more implementations. The company strategy needs explained. Nourish care reseller deal in April 24 hasn't made an impact this year.
With 2 cap raises planned (Dec 24 and June 25) it's SP doldrums for another year without a major announcement.
Add to My Watchlist
What is My Watchlist?
